Edelfosine

Synonyms: ET-18-OCH3
Edelfosine (ET-18-OCH3) 是一种口服有效的脂筏调节剂和凋亡 (Apoptosis) 诱导剂,能够改变膜流动性并优先插入肿瘤细胞膜,通过将死亡受体配体 (FasL/CD95L, TRAIL) 及 Bid 募集至脂筏形成死亡诱导信号复合物,从而启动线粒体依赖的细胞凋亡并诱导细胞色素 c 释放,同时具有抗炎作用,可促进 L-Selectin 脱落且无胃肠道或器官毒性,此外还能抑制杜氏利什曼原虫的核酸与蛋白质合成并具有抗增殖活性,可应用于多发性骨髓瘤、炎症性肠病(如溃疡性结肠炎、克罗恩病)及内脏利什曼病的研究。
产品编号: MS-K15394 纯度: 99.0% CAS No.: 70641-51-9 分子式: C27H58NO6P 分子量: 523.73
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Edelfosine (ET-18-OCH3) 是一种口服有效的脂筏调节剂和凋亡 (Apoptosis) 诱导剂,能够改变膜流动性并优先插入肿瘤细胞膜,通过将死亡受体配体 (FasL/CD95L, TRAIL) 及 Bid 募集至脂筏形成死亡诱导信号复合物,从而启动线粒体依赖的细胞凋亡并诱导细胞色素 c 释放,同时具有抗炎作用,可促进 L-Selectin 脱落且无胃肠道或器官毒性,此外还能抑制杜氏利什曼原虫的核酸与蛋白质合成并具有抗增殖活性,可应用于多发性骨髓瘤、炎症性肠病(如溃疡性结肠炎、克罗恩病)及内脏利什曼病的研究。

生物实验数据

生物活性 Edelfosine (ET-18-OCH3) is an orally active lipid raft modulator and apoptosis inducer that alters membrane fluidity and preferentially inserts into tumor cell membranes, initiating mitochondria-dependent apoptosis and inducing cytochrome c release by recruiting death receptor ligands (FasL/CD95L, TRAIL) and Bid to lipid rafts to form the death-inducing signaling complex, and it also exerts anti-inflammatory effects by promoting L-Selectin shedding without gastrointestinal or organ toxicity, inhibits nucleic acid and protein synthesis in Leishmania donovani with antiproliferative activity, and can be applied in research on multiple myeloma, inflammatory bowel diseases (such as ulcerative colitis and Crohn's disease), and visceral leishmaniasis.
体外研究
(In Vitro)

Edelfosine (10 μM; 24-48 h) 可诱导人多发性骨髓瘤 (MM) 细胞系 (MM144、MM1S、MM1R、RPMI-8226、OPM-2)、白血病 Jurkat T 淋巴系细胞和 JY B 淋巴系细胞中发生细胞凋亡,其中 MM144 细胞的敏感性最高;但不能诱导 Fas/CD95 缺陷型人源 OPM-2 MM 细胞凋亡。
Edelfosine (10 μM; 15 h) 可诱导人 MM144 细胞中诱导 Fas/CD95、DR4、DR5、FADD、procaspase-8、活化的 caspase-8 和 Bid 易位至脂筏中,从而诱导 DISC 形成 (由 Fas/CD95、FADD 和 caspase-8 组成)。
Edelfosine (10 μM; 3-24 h) 可在人 MM144 细胞中诱导细胞凋亡,孵育 15 小时后开始出现该效应,同时在该时间点可检测到 caspase-3 和 PARP 的激活,孵育 24 小时后观察到超过 50%的细胞凋亡。
Edelfosine (5 μg/ml;12 h,18 h) 相较于仅含培养基的对照组,可延缓中性粒细胞的自发性凋亡。
Edelfosine (0.01-5 μg/ml;15 min) 可呈浓度依赖性下调细胞表面 L-selectin、CD43 和 CD44 (但不包括 CD11a、CD11b 或 HLA),其中下调 L-selectin 的 IC50 为 0.29 μM。
Edelfosine (1.9-95 μM;4 h) 可抑制 J774A.1 巨噬细胞内的 Leishmania donovani 无鞭毛体,处理 4 小时后,其 ED50 值在光学显微镜检测下为 19.47 μM,在流式细胞术检测下为 23.16 μM。

Apoptosis Analysis

Cell Line: Human multiple myeloma (MM) cell lines (MM144, MM1S, MM1R, RPMI-8226, OPM-2)
Concentration: 10 μM
Incubation Time: 24 h, 48 h
Result: Induced potent apoptotic responses in all tested MM cell lines. Showed higher sensitivity in MM144 cells (higher cell-surface Fas/CD95 content).
Produced similar apoptotic cell death rates in dexamethasone-sensitive MM1S cells and dexamethasone-resistant MM1R cells.

Immunofluorescence

Cell Line: Human MM144 cells and primary MM cells from patients
Concentration: 10 μM
Incubation Time: 12 h
Result: Potentiated coclustering of lipid rafts and Fas/CD95 in MM144 cells, as shown by yellow colocalization areas in merged confocal images.
Induced similar coclustering in primary MM cells from patients.

Western Blot Analysis

Cell Line: Human MM144 cells
Concentration: 10 μM
Incubation Time: 15 h
Result: Induced translocation of Fas/CD95, DR4, DR5, FADD, procaspase-8, cleaved active caspase-8 forms, and Bid into lipid raft fractions.
Achieved almost complete translocation of Fas/CD95, DR5, FADD, and Bid into lipid rafts.\n
Induced formation of DISC containing Fas/CD95, FADD, and caspase-8 in whole cell lysates and in isolated lipid raft fractions.
Had its induced DISC formation prevented by disruption of lipid rafts with methyl-β-cyclodextrin.

Apoptosis Analysis

Cell Line: Fas/CD95-deficient human OPM-2 MM cells, and OPM-2 cells transduced with full-length Fas/CD95 or truncated FasΔ57C retrovirus
Concentration: 10 μM
Incubation Time: 24 h
Result: Did not induce apoptosis in Fas/CD95-deficient OPM-2 cells. Restored sensitivity to edelfosine in OPM-2 cells transduced with full-length Fas/CD95.
Failed to restore sensitivity in OPM-2 cells transduced with truncated FasΔ57C.
Did not restore Fas/CD95 expression in Fas/CD95-deficient OPM-2 cells, nor increase Fas/CD95 expression in Fas/CD95-positive MM144 cells.

Apoptosis Analysis

Cell Line: Human MM144 cells stably transfected with Bcl-Xₗ (MM144-Bcl-Xₗ) or empty vector (MM144-Neo)
Concentration: 10 μM
Incubation Time: 15 h (cytochrome c release); 24 h (apoptosis)
Result: Induced apoptosis and cytochrome c release from mitochondria to the cytosol in MM144-Neo cells.
Had both induced cytochrome c release and apoptosis prevented by overexpression of Bcl-Xₗ.
体内研究
(In Vivo)

Edelfosine (2.5-5 mg/kg; p.o.; 每日; 21 d) 可使瑞士小鼠中膨润土诱导的足爪水肿分别抑制 34% (2.5 mg/kg) 和 49% (5 mg/kg),且未出现相关的体重下降。
Edelfosine (5 mg/kg; p.o.; 每日) 可在 TNBS 给药后 24 小时将 Wistar 大鼠中 TNBS 诱导的溃疡性结肠炎严重程度降低 45.5%,在给药后 7 天降低 76.5%,同时还能减轻中性粒细胞浸润并促进结肠组织修复。
Edelfosine (40 mg/kg; p.o.; 每日; 4 周) 在健康 Wistar 大鼠中未表现出心脏毒性、肝脏毒性、肾脏毒性或胃肠道组织学损伤,且不会抑制结肠黏膜前列腺素 E2 的合成。

Animal Model: Swiss mice inflammation model
Dosage: 2.5 mg/kg; 5 mg/kg
Administration: p.o.; daily; 21 days
Result: Inhibited inflammation by 34%.\nInhibited inflammation by 49%.\nCaused no body weight loss during treatment.
Animal Model: Wistar rats with Inflammatory bowel disease
Dosage: 5 mg/kg
Administration: p.o.; daily
Result: Protected against TNBS-induced body weight loss.\nReduced colon wet weight.\nInhibited colonic mucosal damage score by 45.5% at 24 hours post-TNBS administration.\nInhibited colonic mucosal damage score by 76.5% at 7 days post-TNBS administration.\nReduced ulcer formation, edema, and inflammatory cell infiltration in colon sections, with focal reparative processes observed.\nDramatically reduced colonic myeloperoxidase and neutrophil elastase activities.\nResulted in only submucosal focal mild inflammatory cell infiltration, compared to widespread intense infiltration in untreated controls.
Animal Model: Healthy Wistar rats
Dosage: 40 mg/kg
Administration: p.o.; daily; 1 week; 4 weeks
Result: Caused no body weight loss or overt toxicity during 4 weeks of treatment.\nShowed no cardiotoxicity, hepatotoxicity, or renal toxicity via biochemical and functional analyses.\nCaused no histologic damage to kidney, liver, heart, or stomach tissue.\nDid not inhibit basal prostaglandin E2 synthesis in rat colonic mucosal samples (78 ± 10 pg PGE2/mg tissue in control vs. 83 ± 9 pg PGE2/mg tissue in treated rats).
性状 固体
颜色 White to off-white

化学信息

分子量 523.73
分子式 C27H58NO6P
CAS No. 70641-51-9
别名 ET-18-OCH3

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (47.73 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.9094 mL9.5469 mL19.0938 mL47.7345 mL
5 mM0.3819 mL1.9094 mL3.8188 mL9.5469 mL
10 mM0.1909 mL0.9547 mL1.9094 mL4.7735 mL
15 mM0.1273 mL0.6365 mL1.2729 mL3.1823 mL
20 mM0.0955 mL0.4773 mL0.9547 mL2.3867 mL
25 mM0.0764 mL0.3819 mL0.7638 mL1.9094 mL
30 mM0.0636 mL0.3182 mL0.6365 mL1.5912 mL
40 mM0.0477 mL0.2387 mL0.4773 mL1.1934 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础